Basic information of Fasl :

Official Symbol of Gene	Fasl
Species	Homo sapiens
Entrez Gene ID	14103
Official Full Name	Fas ligand (TNF superfamily, member 6)
Also known as	gld; CD178; CD95L; Fas-L; Faslg; CD95-L; Tnfsf6; Tnlg1a; APT1LG1
Gene Type	protein coding
dbXrefs	Ensembl:ENSMUSG00000000817 AllianceGenome:MGI:99255
Map Location	1 H2.1; 1 69.95 cM

Sample information of multiple sclerosis:

Detected Sample	Peripheral blood
Sample Detail	N/A
Detected Method	Real-time quantitative PCR
Disease	MS
Disease subtype	RRMS
Population	N/A
Sample Size	15 patients with RRMS

Literature information of multiple sclerosis :

Pubmed ID	26407760
Year	2019
Title	RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis

Results of multiple sclerosis :

Expression	up-regulation
Risk type	Disease risk
Result	Target gene mRNA expression was measured in patients’ isolated PBMCs by real-time qRT-PCR. Compared to stable MS patients, those with acute relapses exhibited decreased expression of RGC-32 (p<0.0001) and FasL (p<0.0001), increased expression of IL-21 (p=0.04), but no change in CDC2 or AKT. Compared to non-responders, responders to GA treatment showed increased expression of RGC-32 (p<0.0001) and FasL (p<0.0001), and decreased expression of IL-21 (p=0.02). Receiver operating characteristic (ROC) analysis was used to assess the predictive accuracy of each putative biomarker. The probability of accurately detecting relapse was 90% for RGC-32, 88% for FasL, and 75% for IL-21. The probability of accurately detecting response to GA was 85% for RGC-32, 90% for FasL, and 85% for IL-21. Our data suggest that RGC-32, FasL, and IL-21 could serve as potential biomarkers for the detection of MS relapse and response to GA therapy.
Mechanism/Pathway	In addition RGC-32 binds to and modulates the activity of AKT , and regulates the expression of FasL and interleukin-21 (IL-21)